Catalog makes Hartwig Medical Database easily searchable
![Catalog makes Hartwig Medical Database easily searchable](https://www.hartwigmedicalfoundation.nl/wp-content/uploads/2023/09/Schermafbeelding-2023-09-29-om-09.02.26.png)
Hartwig Medical Foundation maintains a catalog of the Hartwig Medical Database with whole-genome data on full tumor genomes: https://catalog.hartwigmedicalfoundation.nl. The database currently contains data on over 5,800 patients, including treatment and response data. In addition, this database contains RNA sequencing data from more than half of the patients.
Hartwig Medical Foundation’s mission is to provide the best possible care for today’s patient as well as the patient of tomorrow. An important part of this is making genomic and relevant clinical data available to research groups, with consent from the patients involved. The public catalog of Hartwig Medical Database makes it easy to gain insight into the available data, enabeling a quick and easy overview if there are tumor genomes in the database of interest to the researcher.
![](https://www.hartwigmedicalfoundation.nl/wp-content/uploads/2023/09/Schermafbeelding-2023-09-29-om-09.07.49.png)
The catalog is interactive and the database can be viewed through flexible visualizations of different data types in multiple dimensions. Filtering is possible per data type, e.g. tumor type, biopsy location, age, gender, treatment given, treatment outcome and RNA availability.
This is the world’s largest publicly available dataset of its kind. It is available free of charge for research to improve the care for cancer patients of today and tomorrow. Hartwig Medical Foundation is grateful for the cooperation of so many patients, they have chosen to share their data for the benefit of science and other patients.
For the conditions and procedures for requesting access to the data, please visit our website.
Hartwig Medical Foundation collects data in collaboration with the CPCT, the Netherlands Cancer Institute and more than 40 Dutch hospitals with the consent of patients in various studies.
This unique source is continuously growing with increasing adaptation of complete genome diagnostics in regular healthcare in the Netherlands. Cancer of unknown primary origin is the first indication with a reimbursement title for this test and shows clearly the added value for patients in daily practice.
All news
Also read
![Unique insights in the differences between primary and metastatic cancer by large-scale DNA data analyses](https://www.hartwigmedicalfoundation.nl/wp-content/uploads/2023/05/DNA-kankercel-1024x576.jpg)
Unique insights in the differences between primary and metastatic cancer by large-scale DNA data analyses
Researchers have obtained valuable insights into the development of tumors from a unique Dutch data collection. These insights provide relevant …
![Towards a learning healthcare system by broad collaboration](https://www.hartwigmedicalfoundation.nl/wp-content/uploads/2022/09/Miriam-Koopman-M-001TD.jpg_41-1024x683.jpg)
Towards a learning healthcare system by broad collaboration
Developing a new drug is expensive and takes a long time. In addition, there is only a slim chance that …
![Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs](https://www.hartwigmedicalfoundation.nl/wp-content/uploads/2022/04/Oncode-Pact-Persbericht-beeld-V2-1024x640.jpg)
Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer …
![](https://www.hartwigmedicalfoundation.nl/wp-content/uploads/2023/04/Schermafbeelding-2023-04-14-om-14.55.52.png)
Cancer is caused by DNA mutations. There are an increasing number of drugs available that act on specific errors in the DNA of an individual patient’s tumor. A drug that doesn’t fit, like a key in a lock, will not work, while the risk of side effects remains.